GLAXF News and Press, GlaxoSmithKline Plc From 02/03/22

Fisher’s 13F portfolio value increased from ~$161B to ~$179B in Q4 2021. Amazon, Netflix, Meta Platforms, and PayPal Holdings were increased while reducing Visa, Cisco Systems, Walt Disney, Intel, Wal-Mart, UnitedHealth, and Starbucks this quarter. The top three positions a...

My portfolio, built specifically for my retirement ~20+ years from now, experiences some volatility in January as I start converting conservative investments into riskier assets after big Fed based sell-offs. Making monthly contributions, even though they seem small at the time, makes...

The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021. Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster. Both early clinical assets address a market with a high medical need and have blockbuster ...

As of October, GlaxoSmithKline had 4 drugs in registration and 24 drugs in phase 3 trials. Even though the dividend is going to be cut with a current yield of around 3.43% (55p - from both businesses), 'New GSK' is positioned as a strong GARP play. New GSK has a long way to go to ...

Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022. Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma. The global m...

My portfolio, built specifically for my retirement ~20+ years from now, rides the November volatility in the market as this year's Santa run begins amidst COVID fears. Rivian finally IPOs as I add shares of this EV monster to hopefully follow in the footsteps of Tesla as America's aut...

Two sample Breakout Stocks for Week 48 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the portfolio is up +70.5% YTD despite a record high 26 weeks out 47 weeks this year in n...

VIR's sotrovimab is a monoclonal antibody that binds to a highly conserved domain on the SARS-COV2 virus. The emergence of the South African variant has shown why mAbs are still highly relevant to treating covid-19 patients. Vir's current low prices - despite the small spike recen...

The following slide deck was published by GlaxoSmithKline plc in conjunction with this event. For further details see: GlaxoSmithKline (GSK) Presents At Investor Science Event at ASN Kidney Week 2021

DWX is an international dividend ETF. It is overweight in Europe, utilities and financials. Total return since inception is underwhelming relative to competitors. Why I prefer DNL. For further details see: DWX: Past Performance Is Concerning